Medicine
Redemplo 50 mg/1 mL injection
Redemplo 50 mg/1 mL injection is a prescription medicine containing Plozasiran for subcutaneous use, marketed by Arrowhead Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store REDEMPLO refrigerated at 2°C to 8°C (36°F to 46°F) in the original…
Key facts
- Active ingredient (INN)
- Plozasiran
- Brand
- Redemplo
- Strength
- 50 mg/1 mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 1 syringe of 1 mL
- Marketing authorisation holder
- Arrowhead Pharmaceuticals
- Manufacturer
- Arrowhead Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store REDEMPLO refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton, until ready for use. REDEMPLO prefilled syringe can also be kept at room temperature at 20°C to 25°C (68°F to 77°F) in the original carton for up to 30 days. If not used within the 30 days stored at room temperature, discard REDEMPLO.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- C10AX Cholesterol and lipid-lowering medicines, subgroup C10A, subgroup C10AX
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 19 November 2025
- Identifiers
- RxCUI 2728183, 2728184DailyMed set ID 7fd37993-f85a-4af1-8bbe-133299f226edNDC 84141-025Application NDA219947
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 syringe, glass in 1 carton / 1 mL in 1 syringe, glass | 84141-025-01 | Arrowhead Pharmaceuticals | 19 November 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Plozasiran is an APOC-III-directed RNA interaction indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). It is available as injection for subcutaneous use. MedsAcross supplies Plozasiran for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about PlozasiranFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- REDEMPLO prescribing information (Arrowhead Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Redemplo: European public assessment report (EPAR) · European Medicines Agency
Need Redemplo 50 mg/1 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.